##plugins.themes.bootstrap3.article.main##

Myxedema coma, represents the extreme degree of severity of hypothyroidism, whose mortality can reach very high percentages, therefore, it is a true medical emergency. In general, its development is associated with the presence of a triggering factor in a controlled hypothyroid patient and manifests with multisystem alteration. Currently, tools have been developed for clinical diagnosis that use the profile and clinical models, and have good sensitivity-specificity. They allow an early diagnosis which favored the early start of treatment and therefore improves the prognosis. The patient with myxedema coma needs an integral approach, with intensive treatment and close monitoring of hemodynamic parameters. However, the basis of treatment remains hormone replacement, which should be initiated with a combination of levothyroxine and triiodothyronine.

Downloads

Download data is not yet available.

References

  1. V. Mathew, R.A. Misgar , S. Ghosh, et al. Myxedema coma: a new look in to an old crisis. J Thyroid Res. 2011; 1: 493-462.
    DOI  |   Google Scholar
  2. J. Hampton. Thyroid gland disorder emergencies: thyroid storm and myxedema coma. AACN. Adv Crit Care. 2013; 24:325–32.
    DOI  |   Google Scholar
  3. G. Popoveniuc, L. Wartofsky, et al. A diagnostic scoring system for myxedema coma. Endocrine Practice, 2014; 20: 808-817.
    DOI  |   Google Scholar
  4. Yien V. Chiong. Development of an objective tool for the diagnosis of myxedema coma. Translational Research, 2015, 166(3): 233-245.
    DOI  |   Google Scholar
  5. J. Nicoloff, J. Lopresti. Myxedema coma, a form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993; 22: 279–90.
    DOI  |   Google Scholar
  6. L. Wartofsky, Myxedema Coma. Endocrinol Metab Clinic North America. 2006. 35: 687–698.
    DOI  |   Google Scholar
  7. S. Chakraborty, J. Fedderson, J.J. Gums , Toole A. Amiodarone-induced myxedema coma: a case and review of the literature. Arch Med Sci. 2014; 6: 1263-1268.
    DOI  |   Google Scholar
  8. N. Stathatos, L. Wartofsky. Perioperative management of patients with hypothyroidism. Endocrinol Metab Clin North Am. 2003; 32:503–518.
    DOI  |   Google Scholar
  9. N.O. Turhan, M.C. Kockar, I. Inegol. Myxedematous coma in a laboring woman suggested a pre-eclamptic coma: a case report. Acta Obstet Gynecol Scand. 2004; 83:1089–1891.
    DOI  |   Google Scholar
  10. M. Chu, T.F. Seltzer. Myxedema coma induced by ingestion of raw bok choy, N England J Medicine. 2010. 362(20): 1945–1946.
    DOI  |   Google Scholar
  11. S. Danzi, I. Klein. Thyroid hormone and the cardiovascular system. Med Clin North Am. 2012; 96:257-268.
    DOI  |   Google Scholar
  12. I. Khochtali, N. Hamza . Reversible dilated cardiomyopathy caused by hypothyroidism. International Archives of Medicine. 2011; 4:20-26.
    DOI  |   Google Scholar
  13. R.E Watanakunakorn, R.E Hodges. Myxedema: A Story of 400 Cases. Arch Intern Med. 1965; 116:183-190.
    DOI  |   Google Scholar
  14. J.C. Ravi Shankar, H. Ramesh, N. Hebsur. Hypothyroidism as a Rare Cause for Ogilvie Syndrome. Journal of Dental and Medical Sciences. 2015. 14(4): 32-34.
     Google Scholar
  15. R.W Skowsky, T.A Kikuchi. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 1978; 64: 613–621.
    DOI  |   Google Scholar
  16. V. Sanders. Neurologic manifestations of myxedema. New Engl Journal Medicine. 1962; 266:547–551.
    DOI  |   Google Scholar
  17. T.W Heinrich, G. Grahm. Hypothyroidism Presenting as Psychosis: Myxedema Madness Revisited. Prim Care Companion J Clin Psychiatry. 2003; 5:260–266.
    DOI  |   Google Scholar
  18. I. Espinoza, R. Ramos, A.M Maroon. Myxedema madness. Hipotiroidismo que debuta como psicosis. Rev Psiquiatr Salud Ment. 2010; 3(3): 111–112.
    DOI  |   Google Scholar
  19. W. Reinhardt, K. Mann. Incidence, clinical picture, and treatment of hypothyroid coma: results of a survey. Med Klin 1997; 92: 521–4.
    DOI  |   Google Scholar
  20. A. Kogan, K. Yigal. Severe hypothermia in myxedema coma: A rewarming by extracorporeal circulation. Emergency Medicine Australasia. 2011. 23: 773–775.
    DOI  |   Google Scholar
  21. T. Yamamoto. Delayed respiratory failure during the treatment of myxedema coma. Endocrinol Japan. 1984; 31: 769–775.
    DOI  |   Google Scholar
  22. T.C. Kamilaris, C.R DeBold, S.N. Pavlou. Effect of altered thyroid hormone levels on hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab. 1987; 65:994-999.
    DOI  |   Google Scholar
  23. S. Crunkhorn, M.E. Patti. Links between thyroid hormone action, oxidative metabolism, and diabetes risk? Thyroid. 2008; 18:227-237.
    DOI  |   Google Scholar
  24. Y. Iwasaki, Y. Oiso, K. Yamauchi. Osmoregulation of plasma vasopressin in myxedema. J Clin Endocrinol Metab. 1990; 70:534-539.
    DOI  |   Google Scholar
  25. M. Altay, M. Duranay, M. Ceri. Rhabdomyolysis due to hypothyroidism. Nephrol Dialysis Transp.2004. 20(4): 847–848.
    DOI  |   Google Scholar
  26. Z.Y. Chang, A.Y. Boo. Rhabdomyolysis: A rare complication of hypothyroidism. Proceedings of Singapore Healthcare 2015. 24(3): 188-190.
    DOI  |   Google Scholar
  27. F. Leonard, I. Rizzo, L. Daniela. Coma mixedematoso. Rev Medicina. 2017; 77: 321-328.
     Google Scholar
  28. B. Nygaard. Effect of combination therapy with thyroxine (T4) and 3,5,3-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol 2009; 161: 895–902.
    DOI  |   Google Scholar
  29. E.A. McAninch, A.C. Bianco. New insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism. Lancet Diabetes Endocrinol. 2015; 3: 756–758.
    DOI  |   Google Scholar
  30. J. Garber, R. Cobin, H. Gharib. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 18 (6):1004.
    DOI  |   Google Scholar
  31. J. Jonklaas, C.B. Antonio. Guidelines for the Treatment of Hypothyroidism. Am. Thyroid Assoc. Thyroid. 2014. 24(12): 1670-1752.
    DOI  |   Google Scholar
  32. T. Yamamoto, J. Fukuyama, A. Fujiyoshi. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 2009. 9: 1167–1174.
    DOI  |   Google Scholar
  33. P.W. Ladenson, P.D. Goldenheim, D.S. Cooper, M.A. Miller. Early peripheral responses to intravenous L-thyroxine in primary hypothyroidism. Am J Med. 1982. 73:467–474.
    DOI  |   Google Scholar
  34. K. Boelaert. Prevalence and Relative Risk of Other Autoimmune Diseases in Subjects with Autoimmune Thyroid Disease. American J Med. 2010. 123(12): 1831-9.
     Google Scholar
  35. J.F. Nickerson, S.R Hill, J.H. McNeil, S.B Barker. Fatal myxedema, with or without coma. Ann Intern Med. 1999. 53;175-193.
     Google Scholar
  36. R.M. Jordan. Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Medical Clinics of North America. 1995. 79:185–194.
    DOI  |   Google Scholar
  37. O. Yosuke, O. Sachiko. Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in Japan. Journal of Epidemiology. 2017. 27: 117-122.
    DOI  |   Google Scholar